Valuation: Ipsen S.A.

Market Cap 13.71B 15.77B 12.76B 11.72B 22.12B 1,505B 22.47B 150B 59.03B 749B 59.23B 57.92B 2,513B P/E 2026 *
14.3x
P/E 2027 * 14.7x
Enterprise Value 12.26B 14.11B 11.41B 10.48B 19.79B 1,347B 20.1B 135B 52.81B 670B 52.98B 51.82B 2,248B EV / Sales 2026 *
2.79x
EV / Sales 2027 * 2.5x
Free-Float
40.65%
Yield 2026 *
0.89%
Yield 2027 * 0.92%
1 day+5.19%
1 week+7.51%
1 month+2.16%
3 months+2.77%
6 months+23.30%
Current year+42.36%
1 week 157.2
Extreme 157.2
170.7
1 month 156.7
Extreme 156.7
172.4
Current year 116.4
Extreme 116.4
173.1
1 year 103.7
Extreme 103.7
173.1
3 years 88.3
Extreme 88.3
173.1
5 years 77.62
Extreme 77.62
173.1
10 years 66.65
Extreme 66.65
173.1
Manager TitleAgeSince
Chief Executive Officer 59 2020-06-30
Chief Executive Officer 57 2019-12-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 2005-08-29
Chairman 68 2010-11-21
Director/Board Member 69 2012-05-31
Change 5-day change 1-year change 3-year change Capi.($)
+5.19%+7.51% - - 15.77B
-0.53%-3.95%+50.70%+153.56% 1,024B
+0.21%-2.68%+53.20%+51.79% 618B
-2.51%-3.25%+28.54%+68.94% 443B
+0.06%-0.42%+37.53%+30.67% 349B
-0.69%-0.30%+13.76%+12.83% 264B
-7.37%-4.40%-0.74%-44.28% 209B
-0.64%+2.43%+29.74%+65.93% 208B
-0.82%+0.70%+15.05%+72.05% 162B
+0.40%+1.92%+6.47%-29.77% 143B
Average -0.67%-1.21%+26.03%+42.41% 379.88B
Weighted average by Cap. -0.98%-2.02%+36.14%+71.90%

Financials

2026 *2027 *
Net sales 4.39B 5.06B 4.09B 3.76B 7.09B 483B 7.2B 48.22B 18.92B 240B 18.99B 18.57B 806B 4.55B 5.24B 4.24B 3.89B 7.35B 500B 7.46B 49.95B 19.6B 249B 19.67B 19.24B 835B
Net income 974M 1.12B 907M 832M 1.57B 107B 1.6B 10.69B 4.19B 53.25B 4.21B 4.12B 179B 970M 1.12B 903M 829M 1.56B 106B 1.59B 10.64B 4.18B 53.01B 4.19B 4.1B 178B
Net Debt -1.45B -1.66B -1.35B -1.23B -2.33B -159B -2.37B -15.85B -6.22B -79B -6.24B -6.11B -265B -2.34B -2.69B -2.18B -2B -3.77B -257B -3.83B -25.66B -10.07B -128B -10.11B -9.88B -429B
Logo Ipsen S.A.
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change
26-07-31 €170.40 +5.19%
26-07-30 €162.00 +0.50%
26-07-29 €161.20 +0.81%
26-07-28 €159.90 +0.44%
26-07-27 €159.20 +0.44%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
167.20EUR
Average target price
161.67EUR
Spread / Average Target
-3.31%

Quarterly revenue - Rate of surprise